- Record: found
- Abstract: found
- Article: not found
Mediterranean diet and brain structure in a multiethnic elderly cohort
Read this article at
Abstract
Objective:
To determine whether higher adherence to a Mediterranean-type diet (MeDi) is related with larger MRI-measured brain volume or cortical thickness.
Methods:
In this cross-sectional study, high-resolution structural MRI was collected on 674 elderly (mean age 80.1 years) adults without dementia who participated in a community-based, multiethnic cohort. Dietary information was collected via a food frequency questionnaire. Total brain volume (TBV), total gray matter volume (TGMV), total white matter volume (TWMV), mean cortical thickness (mCT), and regional volume or CT were derived from MRI scans using FreeSurfer program. We examined the association of MeDi (scored as 0–9) and individual food groups with brain volume and thickness using regression models adjusted for age, sex, ethnicity, education, body mass index, diabetes, and cognition.
Results:
Compared to lower MeDi adherence (0–4), higher adherence (5–9) was associated with 13.11 ( p = 0.007), 5.00 ( p = 0.05), and 6.41 ( p = 0.05) milliliter larger TBV, TGMV, and TWMV, respectively. Higher fish (b = 7.06, p = 0.006) and lower meat (b = 8.42, p = 0.002) intakes were associated with larger TGMV. Lower meat intake was also associated with larger TBV (b = 12.20, p = 0.02). Higher fish intake was associated with 0.019 mm ( p = 0.03) larger mCT. Volumes of cingulate cortex, parietal lobe, temporal lobe, and hippocampus and CT of the superior-frontal region were associated with the dietary factors.
Related collections
Author and article information
Contributors
-
Currently serve on the scientific advisory board of Keystone Heart and ProPhase.
-
Editorial board member of The Journal of the International Neuropsychological Society. Editorial board member of Neuropsychology Review
-
Consultant for ProPhase. Years: 2007-2011 and 2013-present. Consultant for Keystone Heart. Years: 2012-Present.
-
grant support: NIH AG029949 PI 2007-2012 NIH AG024708 PI 2004-2006 NIH AG034189 PI 2010-2015 NIH AG043337 PI 2012-2014
-
grant support: Columbia University PI 2008-2009 Columbia University PI 2012-2013
-
grant support: Alzheimer's Association PI 2005-2007 Alzheimer's Association PI 2010-2012 Mary E. Groff Surgical Medical Research and Education Charitable Trust PI 2012-2013
-
2012: (1) Toronto, Canada, Rotman Institute, Annual Baycrest Research Division Conference, Reimbursement;(2) Newark, NJ, Janssen, LLC and Pfizer Alzheimer's Disease Progression Monitoring Advisory Board Meeting, Honorarium; (3) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (4) Boston, Janssen, Global Advisory Committee Meeting for INROADS study, Reimbursement and Honorarium; (5) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; 2013: (6) Nashville, TN, ADCS, Advisory Board Meeting, Reimbursement; (7) , Hawaii, INS, Annual INS Mtg, Honorarium; (8) Florence, Italy, Accera, Inc./NYU,AD PD meeting, Reimbursement; (9) San Diego, CA,ADC, Directors' Meeting, Reimbursement; (10) (11) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (12) Chicago, AbbVie, Advisory Board Meeting, Honorarium; (13) Boston, MA, AAIC Annual Meeting, reimbursement; (14) Turin, Italy, Int'l Association of Logopedics and Phoniatrics, 29th World Congress of the IALP honorarium; (15) Toronto, Canada, MaRS Health and Digital Media Workshop, Reimbursement; (16) Chicago, Takeda Global Research & Development Center, Inc., Adjudication Kick-off Meeting, Honorarium; (17) Milan, Italy, UNIVERSIT? DEGLI STUDI DI MILANO, CATTEDRA DI NEUROLOGIA, 8th Conference of Neurology: Cognitive Reserve in Aging and Alzheimer's Disease, reimbursement; (18) Tel Aviv, Israel, University of Tel Aviv, Annual Brainstorming of AD, reimbursement; (19) Boston, MA, Eli Lilly, Measuring Function in Alzheimer?s Disease Working Group, Honorarium; 2014: (21) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (22) Barcelona, Spain, International Debate on Ageing and mental health, reimbursement; (23) Chicago, AAAS, Symposium: The Science of Resilient Aging, reimbursement; (24) Washington, D.C., IOM, Workshop on Cognitive Aging, reimbursement; (25) Philadelphia, ADNI, Steering Committee Meeting, reimbursement; (26) Boston, MA, Delirium PPG SAB-Planning of 2014, Reimbursement; (27) Copenhagen, Denmark, AAIC Annual Meeting, AIC and Lilly Symposium, Honorarium;(28) Philadelphia, Eli Lilly, Honorarium; (29) Boston, Delta Quest Foundation, Honorarium; 2015, (30) Dallas, TX, Eli Lilly, Working Group Mtg, Honorarium (31) Dallas, TX, Eli Lilly Primary Outcome Mtg, Honorarium;
-
1) Journal of the International Neuropsychological Society, Associate Editor, 1999-2013, Editorial Board 2013- present, 2)Cognitive and Behavioral Neurology, Editorial Board, 2005-present, 3)Neuropsychology, Editorial Board, 2006-present
-
(1) Allergan, (2) Cephalon, (3) Elan, (4) Eisai, (5) Pfizer, (6) Ortho-McNeil Neurologics, (7) Merck &Co, (8) Glaxo Smith Kline, (9) Ely Lily, (10) Janssen Alzheimer Immunotherapy (11) AbbVie Inc. (12) Takeda Global Research & Development Center Inc. (13) Piramal Imaging SA
-
(1) NIH/NIA, R01AG034178, PI, 2009-2014. (2) NIH/NIA, 5R01AG007370-24, PI, 1989-2011. (3) NIH/NIA, (4) NIH/NIA, R01AG037212-05, Co-I, 2010-2015. (5) NIH/NIA, P50 AG08702- 25, Co-I, 1997-2015. (6) NIH/NIA, R01AG038465-04, PI, 2011- 2016. (7) NIH/NIA, R01AG033546-05, PI 2010-2015. (8) NIH/NIA, R01AG026158-09, PI, 2004-2016. (9) NIH/NINDS, R01NS070600-03, Co-I, 2010-2015. (10) NIH/NIA, R37NS029993- 21, Co-I, 2013-2015. (11) NIH, R01AG036469-03, Co-I, 2011- 16. (12) NIH, R01AG041795-01A1, Co-I, 2013-2018. (13) NIA, R01AG043463, Co-I, 2012-2017.
-
(1) The Dependence Scale measures is licensed for use by commercial entities by Columbia University, and I receive funds from these licenses.
-
R01AG038465 Stern (PI) 09/01/11 ? 08/31/16 Exploring Cognitive Aging Ability Using Reference Ability Networks The proposed research program constitutes a major reevaluation of the methods and goals of the study of cognitive aging that should provide major new, integrative, and perhaps simplifying, insights into the neural basis of the most important and central features of cognitive aging. Role: co-I R01AG033546 Stern (PI) 09/15/10 - 05/31/15 Exercise, aging, and cognition: Effect and mechanisms The goal of the proposed study is to extend the investigation of the beneficial effects of aerobic exercise to younger individuals, aged 25-40 and 50-65. Role: co-I R01 AG026158 Stern (PI) 09/15/04 - 08/31/16 Imaging of Cognition, Learning, and Memory in Aging This work will lead to better understanding of how aging and AD pathology impacts on the neural systems that mediate cognitive function and the neural mechanisms that differentiate successful and unsuccessful aging. In turn, it may provide clues for remediating or preventing age-related cognitive changes and delaying the onset of AD. Role: co-I R01NS076837 Cosentino (PI) 09/21/12 - 07/31/17 Examination of the Earliest Symptoms and Biomarkers of FTLD MAPT Carriers This project examines the earliest clinical symptoms of FTLD in carriers of a tau mutation. Role: co-I R01MH101172 Posner (PI) 09/01/11 ? 08/31/16 Imaging Stimulant Effects on Emotional Liability in Children with ADHD Role: co-I R21MH099388 Steinglass (PI) 01/13/14 ? 12/31/15 Multimodal imaging of the Mesocortical system in anorexia nervosa This project will use complementary neuroimaging techniques to study neural circuitry in anorexia nervosa. Using resting state functional neuroimaging, diffusion tensor imaging, and arterial spin labeling we will evaluate the mesocortical system in individuals with anorexia nervosa before and after weight restoration treatment, as compared with healthy controls. Role: co-I R01AG043463 Ochsner (PI) 09/01/12-8/31/17 Understanding cognitive mechanisms of emotion regulation in aging This project seeks to understand the ways in which the psychological and neural mechanisms underlying the cognitive regulation of emotion change in older adults. Role: co-I ADDF Gibson (PI) 01/01/15 ? 12/31/16 Benfortiamine in Alzheimer ?s Disease: A pilot Study This pilot study will test whether a vitamin B1 derivative that increases glucose utilization and diminishes AD symptoms in mouse models will be beneficial in patients with AD. Role: co-I R01AG043679 Gibson, Jordan (co-PIs) 09/01/14-05/31/19 Benfortiamine in Alzheimer ?s Disease: A pilot Study This pilot study will test whether a vitamin B1 derivative that increases glucose utilization and diminishes AD symptoms in mouse models will be beneficial in patients with AD. Role: co-I
-
Alzheimer's disease and associated disorders, editor in chief, 2015-Journal of Alzheimer's Disease, associate editor, 2008-
-
Biessels GJ, Luchsinger JA. Diabetes and the Brain. Humana, Press 2009. Received $509.78 on 04/28/2010
-
Agency: PCORI (Easygrant ID 7160) (J. Luchsinger), Title: Northern Manhattan Hispanic Caregiver intervention Effectiveness Study (NHiCE), Dates: 12/01/2013-11/30/2016, Goals: to compare the effectiveness of 2 dementia caregiver interventions, the New York University Caregiver Intervention, and the translation of the Resources for Enhancing Caregiver?s Health (REACH OUT) in a pragmatic randomized trial of 200 Hispanic relative caregivers of persons with dementia. Role: PI, Agency: NINR (1R01NR014430-01), Title: New York City Hispanic Dementia Caregiver Research Program (NHiRP), Principal investigator: Lucero; Luchsinger (contact); Mittelman, Dates: 06/01/13-05/31/18 Goals: to establish a program of research about Hispanic caregivers of persons with dementia. NHiRP will provide long term follow-up to an existing clinical trial, create a registry of caregivers, and develop an internet based intervention working with caregivers. Responsibilities: PI, Agency: NIDDK, Title: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE; 1U01DK098246). Principal Investigator: D. Nathan, J. Lachin, Dates: 12/01/12-07/31/20, Goals: GRADE is a multi-center randomized clinical trial to evaluate the relative long-term metabolic and clinical effects of four classes of drugs in combination with metformin for the treatment of type 2 diabetes. Responsibilities: PI of Cognitive Coordinating Center. Agency: NIMHD (P60 MD00206), Title: Northern Manhattan Center of Excellence in Minority Health and Health Disparities (NOCEMHD). Principal investigator: J. Luchsinger, Dates: 05/01/09-01/31/15, Goals: this center grant has 3 projects related to minority health including a prospective study of cognition in persons with diabetes, and 2 trials of community participatory research in diabetes and hypertension. Responsibilities: Center director, Agency: NIDDK (2U01DK048404), Title: DPPOS Neurocognitive Reading Center Principal Investigator: J. Luchsinger, Dates: 07/01/09-01/31/15, Goals: Coordinate the administration of neurocognitive assessments in the 26 sites of the Diabetes Prevention Program Outcomes Study (DPPOS) including traning and quality control. This grant is a subcontract to the St. Luke?s Roosevelt Hospital Center DPPOS site (PI: X. P-Sunyer). Responsibilities: principal investigator. Agency: NIMHD (3P60MD000206-09S2), Title: Bioethics in the Northern Manhattan Center of Excellence in Minority Health and Health Disparities (NOCEMHD) Principal investigator: J. Luchsinger. Dates: 09/22/2011-01/31/15, Goals: The goal is to conduct a 1-year bioethics program to address unresolved bioethics issue in minority health research. Responsibilities: principal investigator, Agency: NIMHD (3P60MD000206-09S1), Title: Environmental health disparities in NOCEMHD, Dates: 09/22/2011-01/31/2015 Principal investigator: J. Luchsinger. Goals: This application established the Contextual Health Disparities-Core (COHD) in the Northern Manhattan Center of Excellence in Minority Health and Health Disparities at Columbia University (NOCEMHD) Responsibilities: principal investigator. Agency: NIA (1R01AG037212-01), Title: Epidemiology of Biomarkers of Risk and Progression in Late Onset Alzheimer's Disease. Dates: 04/01/10-03/31/15, Principal Investigator: R. Mayeux, N.Schupf. Goals: To investigate biomarkers that predict Alzheimer?s disease risk. Responsibilities: co-investigator. Agency: NIA (R01AG034189), Title: White Matter Hyperintensities in aging and dementia. Dates: 3/15/10-2/28/15), Principal investigator: A. Brickman. Goals: to investigate the role of white matter hyperintensities ascertained on MRI in cognitive aging. Responsibilities: co-investigator. Agency: NIMH (R01 MH104574-01). Title: Peer-led healthy lifestyle program in supportive housing, Dates: 7/14/14-06/13/19. Principal Investigator: L. Cabassa. Goals: to carry out a clinical trial of a weight loss intervention among persons with severe mental illness. Responsibilities: co-investigator
-
Reimbursement of travel costs associated with serving on the Medical and Scientific Advisory Board of the Alzheimer's Association
-
Travel costs as a speaker at AAIC, Vancouver 2012, Alzheimer's Association (non-profit)
-
Journal of the International Neuropsychological Society, associate editor, 2005 - 2014
-
1) National Institute on Aging, R01 AG028786, Role: Principal Investigator, 09/15/07 ? 06/30/13 (NCE) 2) National Institute on Aging, R01 AG037212, Role: Co-Investigator, 05/01/10 - 04/30/15
-
2) Alzheimer?s Association, IIRG-11-202789, Role: Principal Investigator, 08/15/11 ? 08/14/14
-
support from NIH #P01HD035897(Co-I), (2010 - 2015) NIH #R01AG037212 (Co-PI), (2010-2015) NIH #U01 AG023749 (Co-PI),(2014 - 2019) NIH #P50 AG08702 (Co-I), (2010-2015) NIH #R01AG036040 (Co-I), (2009-2014) NIH #AG034189 (Co-I) (2010-2015) NIH #R01 DE022658 (Co-I) (2013-2016) ADDF (Co-I) ( 2015-2016) NIH R01 AGO43679 (2014-2019)
Journal
Affiliations
Author notes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.